Clinical Trial Update: A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia [Phase 2]

View source ↗

Summary

This document details a Phase II clinical trial comparing flumatinib versus imatinib in Philadelphia chromosome-positive chronic myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Flumatinib (flumatinib)
• Imatinib (imatinib)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Myelogenous Leukemia, Chronic | Phase 2 | Status: UNKNOWN